Join Vishakha Thakrar, OD, FAAO, FSLS, and other leaders at EyeCon 2025! Hear about the latest advances in eye care and earn up to 14 CME/COPE credits. Sign up NOW and use code THAKRAR to save on registration. Click here:

A study published in Ophthalmology Science shows that by analyzing up-to daily home OCT images, artificial intelligence (AI) can accurately track disease activity in patients with wet age-related macular degeneration (AMD).

Glaucoma techniques advance with innovative viscoelastic delivery. Surgical tools improve Schlemm canal access and enable earlier glaucoma care.

Long-term cannabis use might play a role in reducing proliferative vitreoretinopathy development, according to first author Ahmed M. Alshaikhsalama, MD. He is from the Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas.

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Outlook Therapeutics’ biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD).

Surgical innovation in dry eye disease: Salivary gland transplant. A novel use of minor salivary glands offers lasting relief and visual improvement.

identifeye HEALTH has launched its retinal screening platform and is now delivering results to patients through clinics and community programs.

Zhehuan Zhang, MD, and colleagues emphasized the importance of patients undergoing routine OCT scans during repeated low-level red-light therapy in order to detect retinal changes.

Join Jessica Steen, OD, FAAO, Dipl ABO, and other leaders at EyeCon 2025! Hear about the latest advances in eye care and earn up to 14 CME/COPE credits. Sign up NOW and use code STEEN to save on registration. Click here:

Cataract surgery in patients who have previously undergone refractive procedures, such as LASIK or radial keratotomy (RK), presents unique challenges, noted Steven J. Dell, MD, during an Ophthalmology Times Case-Based Roundtable.

Kriya Therapeutics reported in an SEC filing it has raised $313.3 million in a recent funding round. The filing does not detail fund specificity or funding sources but rather only states two investors participated in the funding push.

Join Prem Subramanian, MD, PhD, and other leaders at EyeCon 2025! Hear about the latest advances in eye care and earn up to 14 CME/COPE credits. Sign up NOW and use code SUBRAMANIAN to save on registration. Click here:

Long-term cannabis use might play a role in reducing proliferative vitreoretinopathy (PVR) development.

Under-eye filler: Cannula vs needle in tear trough treatment. Understand the anatomical risks, technique-specific benefits, and patient selection criteria.

When propofol is used to sedate patients and during periocular injection, the stage may be set for a sneeze reflex. To circumvent this risk, Jeremiah Tao, MD, advises using the opioids.

Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering IOP from baseline in open-angle glaucoma or ocular hypertension patients compared to the standard of care, latanoprost 0.005%.

Caught in the middle of a political battle, @BlackRock reaffirmed its focus is helping millions of Americans save for retirement. They warned that injecting politics from either side risks undermining financial performance.

Meet the expert faculty leading IKA 2025. Gain valuable insights and practical tools to improve keratoconus management and earn COPE CE/CME credits at this live event. Read more:

The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of 2025.

The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of 2025.

A recent study identified a large disconnect between patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) who are treated with intravitreal injections.